Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1538262 | 0.78 | RAB9A (0.55) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL2885830 | 0.77 | RAB9A (0.42) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL15290701 | 0.77 | RAB9A (0.62) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL15290694 | 0.77 | RAB9A (0.58) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL27291761 | 0.77 | RAB9A (0.53) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL23650 | 0.76 | MMP2 (0.40) | CA2CA12ALDH1A1GAACA9 | |
| SCHEMBL15290697 | 0.75 | RAB9A (0.56) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL11314452 | 0.75 | RAB9A (0.56) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL30410947 | 0.75 | RAB9A (0.56) | RAB9ACA2CA12CCNB2CDK1 | |
| SCHEMBL8531145 | 0.75 | RAB9A (0.56) | RAB9ACA2CA12CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
| EP-1147089-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042020-A1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | RAB9A 2699/4885CA2 2608/4885CA12 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.